Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib

MT Newswires Live

06/01

Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.

Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.

Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.

Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2640953136"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640953136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640953136?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640953136","market":"hk","top_or_hot":-1,"title":"Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib","media":"MT Newswires Live","content":"<html><body><p> Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.</p><p>Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.</p><p>Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.</p><p>Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.</p><p>Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.</p><p>Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.</p><p>Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640953136","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640953136","pubTimestamp":1780309879,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Agios Pharmaceuticals  secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Agios Pharmaceuticals与Oscotec签署Cevidoplenib全球许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1.5},"content_text":"Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}